1884269-07-1

1884269-07-1 structure

Name: AHU377-d4
Chemical Name: AHU377-d4
CAS Number: 1884269-07-1
Molecular Formula: C₂₄H₂₅D₄NO₅
Molecular Weight: 415.515
Catalog: Signaling Pathways Metabolic Enzyme/Protease Neprilysin
Create Date: 2021-05-01 17:36:56
Modify Date: 2024-01-08 16:56:42
Sacubitril-d4 (AHU-377-d4) is the deuterium labeled Sacubitril. Sacubitril (AHU-377) is a potent NEP inhibitor with an IC50 of 5 nM. Sacubitril (AHU-377) is a component of the heart failure medicine LCZ696.

Name	AHU377-d4
Synonyms	AHU377-d4 4-{[(2S,4R)-1-(4-Biphenylyl)-5-ethoxy-4-methyl-5-oxo-2-pentanyl]amino}-4-oxo(2H4)butanoic acid [1,1'-Biphenyl]-4-pentanoic acid, γ-[(3-carboxy-1-oxopropyl-2,2,3,3-d4)amino]-α-methyl-, α-ethyl ester, (αR,γS)-

Description	Sacubitril-d4 (AHU-377-d4) is the deuterium labeled Sacubitril. Sacubitril (AHU-377) is a potent NEP inhibitor with an IC50 of 5 nM. Sacubitril (AHU-377) is a component of the heart failure medicine LCZ696.
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> Metabolic Enzyme/Protease >> Neprilysin
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Ksander GM, et al. Dicarboxylic acid dipeptide neutral endopeptidase inhibitors. J Med Chem. 1995 May 12;38(10):1689-700. [3]. Voors AA, et al. The potential role of valsartan + AHU377 ( LCZ696 ) in the treatment of heart failure. Expert Opin Investig Drugs. 2013 Aug;22(8):1041-7. [4]. von Lueder TG, et al. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ Heart Fail. 2015 Jan;8(1):71-8.